Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML

Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term…